e-NIOS

News

New publication involving BioInfoMiner analysis suggests induction of IRE1α-dependent Anticancer Immunosurveillance by low-protein diet (Cell Metabolism)

A new paper involving the participation of e-NIOS and a BioInfoMiner-derived biomarker signature was published in the high impact journal Cell Metabolism.

Dietary restriction was shown to impact on tumor growth with very variable effects depending on the cancer type. However, how dietary restriction limits cancer progression remains largely unknown. In this publication,  we demonstrate that feeding mice a low-protein isocaloric diet but not a low-carbohydrate diet reduced tumor growth in three independent mouse cancer models. Surprisingly, this effect relies on anticancer immunosurveillance. Mechanistically, we established that a low protein diet induces the unfolded protein response (UPR) in tumor cells through the activation of IRE1α and RIG1 signaling, thereby resulting in cytokine production and mounting an efficient anticancer immune response.

http://www.cell.com/cell-metabolism/fulltext/S1550-4131(18)30120-7

Figure thumbnail fx1

 

New paper involving BioInfoMiner analysis validates proteostasis imbalance as a driver of tumor aggressiveness in Glioblastoma (EMBO Mol. Med.)

Proteostasis imbalance is emerging as a major hallmark of cancer, driving tumor aggressiveness. Evidence suggests that the endoplasmic reticulum (ER), a major site for protein folding and quality control, plays a critical role in cancer development. This concept is valid in glioblastoma multiform (GBM), the most lethal primary brain cancer with no effective treatment.

It was previously demonstrated that the ER stress sensor IRE1α (referred to as IRE1) contributes to GBM progression. The new study entitled “Dual IRE1 RNase functions dictate glioblastoma development” published in EMBO Molecular Medicine provides the first demonstration of a dual role of IRE1 downstream signaling in cancer and opens a new therapeutic window to abrogate tumor progression.

BioInfoMiner analysis was employed in order to define specific IRE1‐dependent gene expression signatures that were confronted to human GBM transcriptomes and shed light to the antagonistic roles of XBP1 mRNA splicing and RIDD on tumor outcomes, mainly through selective remodeling of the tumor stroma.

The research was carried out by an international consortium with the participation of e-NIOS, including among others Université de Bordeaux, Université de Rennes 1, University of Ireland Galway, University of Chile, INSERM, CNRS, National Hellenic Research Foundation and Harvard School of Public Health.

 

e-NIOS selected for participation in the PERMIDES project

A joint project between e-NIOS and Genosalut genomics company is among the 25 best-ranked projects funded by a PERMIDES Innovation Voucher.

The project, entitled “Prioritization and pathway Analysis by MachinE LeArning”, aims at the development of an innovative precision medicine application, which integrates clinical and computational expertise, as a decision support tool for diagnosis and treatment of complex diseases.

PERMIDES is one out of five European INNOSUP-1-2015 – Cluster facilitated projects for new value chains (funded under EC Call for proposal: H2020-INNOSUP-2015-1), promoting innovation in Personalized Medicine as an Emerging Industry in Europe. PERMIDES targets key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology.

 

“DISCOVER” Horizon 2020 research proposal approved

e-NIOS will be joining soon another international interdisciplinary research network (Greece, Ireland, France, Switzerland, Turkey), which will bring together experts in the fields of immunology, cancer cell biology, systems biology and pre-clinical drug development, in order to investigate tumour – immune cell interactions for the development of new cancer therapies.

shutterstock_581843374s

eNIOS joins the train-ERS H2020-funded innovation network

eNIOS joins as partner organization the train-ERS H2020-funded innovation network, promoting the understanding of the Endoplasmic Reticulum Stress Response and the identification of innovative strategies for the treatment of ER stress-associated diseases: http://www.train-ers.eu/

Kick-off meeting of the INNOCENT consortium

e-NIOS is a partner of the “INNOCENT” consortium (Slovakia, Greece, Norway, Spain, Latvia, ), funded by a EuroNanoMed II ERA-NET grant, aiming at the development of innovative multifunctional nanopharmaceuticals for breast cancer treatment, with emphasis on cancer stem cells.

e-NIOS joins IPEM 2017

e-NIOS will be joining IPEM 2017 (www.ipem-market.com) at Palais des Festivals, Cannes, France, 25-27 January, as a part of the Greek delegation of innovative companies selected by EASME.